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Addendum to the main text
(i)  ATE1-/- embryos from ATE1+/- intercrosses were present at the expected (~25%) frequency up
to ~E13.5, but virtually no ATE1-/- embryos were recovered alive by E17.  Specifically, no ATE1-/-
mice were recovered amongst either 954 F2-generation pups of the C57BL/6J-129SvEv (mixed)
background or 267 F2-generation pups of the 129SvEv (inbred) background.  Timed intercrosses
of ATE1+/- mice were used to determine that ATE1-/- embryos were present at approximately the
expected (25%) frequency up to ~E13.5, but no ATE1-/- embryos were recovered alive by E17.
Until E12.5, ATE1-/- embryos appeared to be morphologically normal;  however, their growth
stopped during E13.5-E15.5.  By E14.5-E15.5, ~50% of ATE1-/- embryos were still alive, but
growth-retarded.  Live E14.5-E15.5 embryos were capable of opening their mouths and flexing
their bodies, suggesting the absence of gross neuromuscular defects.  Sections through E13.5
ATE1-/- embryos indicated the presence and apparently normal appearance of major organs, except
for the phenotypes described in the main text and below.
(ii)  We examined the expression of ATE1 mRNA during embryogenesis using Northern
hybridization with total RNA from +/+ embryos ranging in age from E4.5 to E18.5.  ATE1 mRNA
was present at least as early as E4.5, and a strong spike of ATE1 expression was observed during
E7.5-9.5 (Fig. S1E).  The ~2 kb ATE1 transcript detected in adult mouse testis (1) was also clearly
present during the spike of ATE1 expression in E7.5-E9.5 embryos (Fig. S1E).  The ATE1- allele
was marked with NLS-β-galactosidase (hereafter βgal), expressed from the ATE1 promoter
(Fig. S1A).  During E9.5-E12.5, the expression of ATE1 (βgal) was high in the neural tube,
including the floor plate, motor neurons, and the neural fold;  ATE1 was also expressed in dorsal
root ganglia, sympathetic ganglia and notochord, in neurons that regulate blood vessels, in sharply
delineated subsets of myotomal cells in each somite, in the mesonephric vesicles (kidney
precursor), in the gut, in specific areas of the eye primordium, at the tips of limb buds, in the
endodermal layer of the yolk sac (but not in its mesodermal layer), and in specific areas of
embryonic heart, including trabeculae, atrial septum, endocardial cushion, aortic valve, and aorta
(Fig. S2).  We also used whole-mount in situ hybridization to examine the expression of ATE1 in
E10.5 +/+ embryos.  Higher levels of ATE1 mRNA expression, as detected through in situ
hybridization, were observed in subsets of myotomal cells in each somite, in the surface ectoderm
of limb bud, in the eye primordium, and in the heart (Fig. S2).
(iii)  Formation of the two ventricular chambers involves proliferation and maturation of myocytes
in the compact muscular layer, accompanied by trabeculation inside the chamber.  The septum is
formed through condensation of trabeculae at the interventricular groove, with the medial walls of
expanding ventricles fusing together, growing inward, and forming the muscular portion of
septum (2).  The defects of ATE1-/- hearts described in the main text suggest that the loss of
R-transferase activity inhibits proliferation of myocardial cells.  In addition, the PTA defect occurs
when too few of the neural crest-derived cells populate the cardiac outflow tract, resulting in a
failure to separate the common truncal outflow vessel into the aorta and pulmonary artery (3).
Since ATE1 is highly expressed in structures produced by cells originating in the neural crest
(Fig. 1 of the main text), the PTA defect of ATE1-/- hearts suggests that the R-transferase activity
may also be required for migration and/or differentiation of neural crest-derived myocardial cells.
(iv)  Angiogenic defects in, for example, the yolk sac of an ATE1-/- embryo (Figs. 2B, F and
S4B, D) might stem, at least in part, from the (expected) pumping defects of abnormal ATE1-/-
heart.  To address this possibility, we compared cardiac defects of ATE1-/- embryos and their
angiogenic defects in yolk sacs.  E13.5-E14.5 embryos were individually scored for angiogenic
defects, such as thin primary vessels and poorly organized small vessels, before determining their
genotype.  The hearts of ATE1-/- embryos thus identified were then examined by serial sectioning
and staining.  Amongst  13 extensively examined ATE1-/- embryos, only one had an apparently
normal heart (Fig. S4E-H);  yet, similarly to other ATE1-/- embryos, it exhibited angiogenesis
defects in the yolk sac (Fig. S4B, D), suggesting that abnormal angiogenic remodeling was not
caused by the cardiogenic defects of ATE1-/- embryos.
(v) To begin a search for mouse genes whose expression is significantly altered in the ATE1-/-
background, we carried out RT-PCR and Northern analyses with total RNA from +/+ and
littermate ATE1-/- embryos proper, their yolk sacs, and their hearts, using mouse cDNA probes
specific for genes that encode the following proteins:  NTAN1, UBR1, UBR2 (components of the
N-end rule pathway (4));  eHand, ICAM2, GATA6, Nfarc1, dHand, NF1, RXRα, FOG2, GATA4,
MEF2c, Neuropilin 1, TEF1, N-myc, RARα, ErbB2 (proteins whose functions include heart
development);  TIE1, TIE2, FLK1, FLK2, FLT1, FLT4, βH1, GATA1, Il-3R, CD34, VEGF,
VEGF-B, VEGF-C, VEGF-D, ANG1, ANG2, ANG3, EfnB1, EfnB2, EfnA1, EphB2 (proteins
whose functions include vascular development).  No significant differences were detected in the
expression of these genes between the ATE1-/- and +/+ genetic backgrounds (data not shown),
making it more likely that the absence of N-terminal arginylation impacted a previously
undescribed circuit.  
Methods
Construction and characterization of ATE1-/- mouse strains
Mouse ATE1 was isolated using screening, with an ATE1 cDNA fragment (nt 638-1,491), a BAC
library (Genome Systems) from 129/SvJ ES mouse cells (1).  The exon/intron organization of the
first ~20 kb of ATE1 was determined using exon-specific PCR primers to produce genomic DNA
fragments flanked by exons.  Details of the targeting vector construction (Fig. S1A) are available
on request.  The vector was linearized with HindIII and electroporated into CJ7 embryonic stem
(ES) cells, followed by selection and identification (4, 5) of the correctly targeted ATE1+/- ES
cell clones with normal karyotype.  Standard techniques (4-6) were then used to produce
chimeric and (subsequently) ATE1-/- mice.  Phenotypes of ATE1-/- embryos were observed
mainly with mice of the C75BL/6J-129SvEv (mixed) background, and confirmed in the
129SvEv (inbred) background.  RT-PCR, Southern and Northern analyses, and PCR-mediated
genotyping of embryos and pups were performed as described (4-7).
R-transferase assay
Ub-X-βgal proteins were purified from E. coli carrying pKKUbXβgal plasmids (8).  The
R-transferase reaction (50 µl) contained S105 supernatant (0.5 mg of protein per ml) from either
EF cells or whole embryos, prepared as described (9), Ub-X-βgal or α-lactalbumin (0.2 mg/ml),
E. coli tRNA (1 mg/ml), E. coli aminoacyl-tRNA synthetases (50 µg/ml), puromycin (0.2 mM),
bestatin (0.15 mM), 5 mM MG132 (proteasome inhibitor), 0.4 mM Lys-Ala dipeptide (inhibitor
of post-arginylation steps in the N-end rule pathway), 1 mM ATP, 10 mM creatine phosphate,
0.1 M KCl, 5 mM MgCl2, 50 mM β-mercaptoethanol, 50 mM Tris-HCl (pH 8.0) and 0.3 mM
3H-arginine (New England Nuclear).  The reaction mixture was incubated for 3 hr (2 hr with
embryo extracts) at 37ºC.  A 20-µl sample was precipitated with 10% TCA, and analyzed by
SDS-12% PAGE and fluorography.
Pulse-chase assays
Primary mouse EFs were established from E13.5 ATE1-/- and littermate +/+ embryos as
described (5), and immortalized (4) to increase transfection efficiency.  Cells were transiently
transfected with pcDNA3flagDHFRhaUBXnsP4flag, which encoded X-nsP4f, a set of 69K
flag-tagged Sindbis virus RNA polymerase proteins bearing different N-terminal residues (4).
X-nsP4f proteins were expressed from the PCMV promoter as parts of fDHFRh-UbR48-X-nsP4f
fusions, the constructs of the UPR (Ub/protein/reference) technique (10-13).
fDHFRh-UbR48-X-nsP4f is cotranslationally cleaved by deubiquitylating enzymes at the UbR48-X
junction, yielding the long-lived, epitope-tagged fDHFRh-UbR48 reference protein and a test
protein X-nsP4f (4).  Superscripts “f” and “h” denote, respectively, the flag and ha epitopes (6).
Cells were labeled with 35S-EXPRESS (New England Nuclear) for 10 min at 37ºC, followed by
a chase for 0, 1, and 2 hr in the presence of cycloheximide, preparation of extracts, precipitation
with anti-flag antibody, SDS-10% PAGE, autoradiography, and quantitation using
PhosphorImager (4, 5, 11).  In other pulse-chases, ATE1-/- EFs were co-transfected with a
plasmid expressing X-nsP4f (fDHFRh-UbR48-X-nsP4f) and either pCDNA3yATE1, expressing
S. cerevisiae ATE1, or pCDNA3yATE1C23A (derived from a plasmid (14) supplied by
Dr. C. Pickart, Johns Hopkins University), which expressed ATE1C23A, bearing Cys→Ala
mutation at position 23.
Protein sequencing
Mouse L cells were transiently transfected with pCDNA3RGS4flagHisx6, which expressed
mouse RGS4-flag-His6 from the PCMV promoter and was constructed from the pCDNA3RGS4
plasmid (15).  Cell extracts were prepared 30 hr later;  RGS4-flag-His6 was purified using
Ni-NTA magnetic agarose beads (Qiagen), then treated with 25 mM iodoacetamide in 7 M urea
(6), followed by SDS-PAGE, the transfer to Immobilon-P membrane, and sequencing by Edman
degradation, using the 476A sequencer (Perkin-Elmer).  For mass spectrometry, RGS4-flag-His6
was treated with 90 mM iodoacetic acid in 8 M urea for 50 min at ~20ºC, then cleaved with
CNBr in 55% HCOOH under argon atmosphere for 12 hr in the dark, followed by reverse-phase
HPLC and on-line, fragmentation-based mass spectrometric sequencing of peptides.
LacZ staining, immunohistochemical staining, apoptosis assay, and in situ hybridization
For histological examination, embryos were fixed in 4% paraformaldehyde, paraffin-embedded,
sectioned, and stained with hematoxylin and eosin.  For LacZ staining, embryos, tissues or yolk
sacs were removed, fixed in 0.25% glutaraldehyde/PBS for 5 min, rinsed twice with PBS, and
stained for 6 hr to overnight at 37°C in X-Gal buffer (1.3 mg/ml potassium ferrocyanide, 1 mg/ml
potassium ferricyanide, 0.2% Triton X-100, 1 mM MgCl2, and 1 mg/ml X-Gal in PBS
 (pH 7.2)).
LacZ-stained embryos were post-fixed, photographed, and sectioned after embedding in 30%
sucrose/PBS or paraffin.  Procedures for whole-mount or section staining with anti-PECAM-1
antibody (clone MEC 13.3, Pharmingen) were done as described (15), using HRP-conjugated
secondary antibody (Jackson Laboratory).  Apoptosis was analyzed by TUNEL labeling with in
situ cell death detection kit (Boehringer Mannheim) using fluorescein-dUTP.  For in situ
hybridization, 1.2 kb ATE1 cDNA fragment (nt 638-1,734) was used as a template for
synthesizing either antisense- or sense-strand RNA probes labeled with digoxigenin (6, 16).
Fig. S1. Construction and characterization of mouse ATE1-/- strains.  (A) Top, a map of the
~20 kb 5’-proximal region of the ~274 kb mouse ATE1 gene.  Middle, the knockout (KO) vector.
Bottom, the deletion-disruption ATE1- allele, which lacked the ATE1 exons 1-3.  ATE1-/- cells
that have been produced through the use of this allele were completely devoid of R-transferase
activity, in contrast to congenic +/+ cells (Figs. 3A, S5A).)  Solid vertical rectangles, solid and
wavy horizontal lines denote, respectively, the exons, the mouse DNA and the pBR322 DNA.
The directions of transcription of NLS-lacZ (NLS-βgal), neo (neomycin), and tk (thymidine
kinase) are indicated by arrows.  H, HindIII; N, NcoI; X, XhoI; B, BamHI.  (B) Southern analysis
of ATE1, using a 0.57 kb 5’-probe, a 0.45 kb 3’-probe (indicated by black rectangles in A), and
HindIII/BamHI-cut genomic DNA from +/+, ATE1+/-, and ATE1-/- E13.5 embryos.
(C) Genotyping E13.5 progeny of an ATE1+/- intercross.  DNA bands corresponding to the
wild-type and mutant ATE1 alleles are indicated on the right.  (D) Northern analysis.
Electrophoresed total RNA from E13.5 embryos was hybridized with cDNA probes specific for
the deleted region of ATE1 cDNA (nt 132-357, Acc. #AF079096) (upper panel), and with β-actin
cDNA (lower panel).   (E) Northern blot analysis with total RNA from different ages of
embryos.  Probes were cDNA fragments specific for ATE1 (nt 638-1,734), UBR1 (nt 116-1,265;
AF061555), UBR2 (nt 2,763-4,923, unpublished) and β-actin.  The bottom panel shows
ribosomal RNA bands stained with ethidium bromide.
Fig. S2. Expression of lacZ (βgal)-marked ATE1- allele (ATE1nlsLacZ) of the ATE1 gene during
embryogenesis.  (A) Whole-mount X-Gal staining of an E10.5 ATE1+/- embryo.
(B-C) Whole-mount X-Gal staining of an E12.5 +/+ (B) and ATE1-/-  (C) embryo.  At this age
(E12.5), ATE1-/- embryos seemed largely normal, albeit already growth-retarded.
(D-H) Transverse sections of E9.5 ATE1+/- embryo.  (D) Caudal trunk section, with prominent
βgal expression in the neural tube (n) and a subset of myotome (arrowhead).  (E) The lens and
surrounding structures of embryonic eye.  (F) Mesonephric vesicles (kidney precursor).
(G) Gut (g).  (H) Floorplate (fl) of the neural tube, notochord (no), and sympathetic
ganglion (sg).  (I-L)  ATE1-/- (E10.5) embryos were used here, in part because their βgal staining
was disproportionately (more than 2-fold) stronger than with ATE1+/- embryos, while being
essentially the same in its spatial distribution and relative intensities (17).  (I) High βgal levels in
the neural tube, motor neuron (mn), dorsal root ganglion (dg), sympathetic trunks (st) between
midline dorsal aorta (do) and subcardinal vein (sv), and in a subset of myotomal cells of each
somite (arrowheads).  ATE1 (βgal) expression was also high in specific myotomal cells of each
somite (black arrowheads);  see (D) for the equivalent spots of βgal expression in a transverse
section of an E9.5 ATE1+/- embryo).  (J-K) Expression of βgal was higher in the right dorsal
aorta (a) (J) than in veins (K).  (L) Expression of βgal in a ganglion (g) near the primary head
vein (v).  (M) Staining with antibody to smooth muscle α-actin identified the myotomal regions
(denoted by dashed white ovals) that included the spots of βgal (ATE1) staining indicated by
arrowheads in (D), (I) and (S);  these spots corresponded to narrow rings of ATE1 expression in
the intact somites.  (N) βgal expression at the tip of forelimb bud.  (O) Cross section of E10.5
ATE1+/- yolk sac.  me, extraembryonic mesoderm; en, extraembryonic endoderm.  (P, Q) ATE1
mRNA, detected by in situ hybridization, in E10.5 +/+ embryos.  Whole-mount in situ
hybridization was carried out with antisense (P) or sense (Q) ATE1 RNA probes (see Methods).
(R-U) Transverse sections of E10.5 embryo shown in (P).  (R) The lens.  (S) A caudal trunk
section showing the expression of ATE1 mRNA in the myotomal regions (arrowheads);  these
spots of ATE1 hybridization corresponded to βgal staining indicated by arrowheads in (D) and
(I).  (T) The heart.  (U) Forelimb bud (compare with panel N).  (V) Hematoxylin/eosin-stained
transverse section of E13.5 ATE1+/- heart that had been whole-mount-stained with X-Gal.  AoV,
aortic valve;  AS, atrial septum;  EC, endocardial cushion.  Bars: 0.5 mm (A-C and P),
50 µm (D-O, R-S and U), 20 µm (T) and 100 µm (V).  
Fig. S3. Perturbation of angiogenesis in ATE1-/- embryos.  (A) Whole mounts of E15.5 ATE1-/-
embryos showing edema (double arrows).  (B, C) Increased apoptosis, detected using the TUNEL
assay (6), in the edematous region (dorsal area, sagittal sections) of the above  ATE1-/- embryo.
(D, E) Cross sections of similarly located areas in yolk sacs of E13.5 +/+ (D) and
ATE1-/- (E) embryos that had been whole-mount stained with anti-PECAM-1 antibody, and
counter-stained with eosin.  Note characteristically smaller collecting vessels in ATE1-/- sacs.
(F, G) Apparently normal intersomitic arteries but poor development of vessels (indicated by
arrowheads) that sprout from these arteries in E9.5 ATE1-/- embryos (F versus G).  (H-K) One
example of impaired angiogenesis in ATE1-/- embryos was the head’s dorsal area in E13.5
+/+ (H, J) and ATE1-/- (I, K) embryos whole-mount stained with anti-PECAM-1 antibody.  Dorsal
(H, I) and lateral (J, K) views of the heads.  This area was a major site of hemorrhages in ATE1-/-
embryos (see the main text and its Fig. 1E.).  Bars: 2 mm (A), 200 µm (B, C), 100 µm (D, E),
250 µm (F, G), and 1 mm (H-K).
Fig. S4. Apparently normal cardiogenesis and abnormal angiogenesis in an ATE1-/- embryo.  (A-
B)  E15.5 +/+ (A) and ATE1-/- (B) embryos, with yolk sacs and ectoplacental cones intact.  The
exceptional ATE1-/- embryo of this example had the heart of apparently normal appearance (E-H),
in contrast to other 12 extensively examined ATE1-/- embryos.  In addition to a growth retardation
of the E15.5 ATE1-/- embryo, typical of ATE1-/- embryos after day ~E12 (A versus B), the ATE1-/-
yolk sac was pale, with thinner and scarcer blood vessels.  (C-D) Similarly located areas of +/+
and ATE1-/- yolk sacs of the same embryo as above, stained with anti-PECAM-1 antibody.  The
obvious difference in the vascular patterns observed (C versus D) is quite similar to that in
Fig. 2E, F of the main text, in which these patterns are of ATE1-/- embryo with an overtly
abnormal heart.  (E-H)  Serial transverse sections of the apparently normal heart of the same
(exceptional) ATE1-/- embryo.  No +/+ heart is shown here;  for the appearance of +/+ hearts, see
Fig. 1I of the main text.  Bars:  1 mm (A-B), 100 µm (C-D), and 200 µm (E-H).
Fig. S5. N-terminal arginylation, and oxidation of N-terminal Cys.  (A) Cell-free assay for mouse
R-transferase using 3H-Arg, S105 extracts from +/+ and ATE1-/- embryos, and unlabeled X-βgals
(X = Cys, Asp, Glu, Met, Arg) as well as α-lactalbumin as test substrates.  Arginylated substrates
are indicated on the right.  An asterisk and bracket indicate arginylated endogenous proteins in the
extracts.  (B) Mouse ATE1-/- EF cells were co-transfected with a plasmid expressing X-nsP4f
(fDHFRh-UbR48-X-nsP4f) and a plasmid expressing either wild-type S. cerevisiae ATE1
(pCDNA3yATE1) or its enzymatically impaired mutant (pCDNA3yATE1C23A) (14).  Cells were
pulse-labeled for 10 min with 35S-methionine, and chased for 1 and 2 hr. (C) Quantitation of
results in (A).  For each time point, the ratio of 35S in X-nsP4f (X = Arg, Asp, Glu, Cys) to 35S in
the fDHFRh-UbR48 reference, at the same time point, was plotted as the percentage of this ratio
relative to that for Met-nsP4f at time 0 (4, 10-12).  Curve designations:  Met-nsP4f coexpressed
with either a vector alone (open green square), or yeast ATE1 (solid green square), or mutant yeast
ATE1 (solid black square).  Cys-nsP4f:  the same except for diamonds instead of squares, and red
instead of green.  Asp-nsP4f:  the same except for circles instead of squares, and blue instead of
green.  (D) The N-terminal sequence of mouse RGS4 deduced from mass spectrometric data
in (E).  The Mr of residue 2 (Cys-2 in the arginylated RGS4) identified it as cysteic acid (Mr of
151.1 Da, 48.1 Da higher than Mr of Cys).  M* denotes homoserine lactone.  (E) Mass
spectrometric analysis of the CNBr-produced 19-residue N-terminal peptide of RGS4.  The
observed molecular masses of peaks are shown in red.  The differences between observed and
expected values are shown in blue.
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